Research
Hormonal
Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.
There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.
LimitedConditionalLOW confidence
This hypothesis (Fig. 1D) would be unifying to explain how both agonism and antagonism support weight loss, but it is not yet bolstered by substantial evidence for desensitization of CNS GIPR activity in one or more neuronal populations.
Why this rating
Supported by adipocyte data but explicitly lacking CNS evidence; considered a hypothesis rather than established fact.
Source
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Jonathan E. Campbell et al. · Diabetes · 2025
DOI 10.2337/db25-0393
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →